Effectiveness | ||||
General | UK variant | South Africa variant | Brazil variant | |
![]() ![]() | 78 % | 70-80% | 10% | yes |
![]() ![]() | 95 % | 90-95% | 62% | yes |
![]() | 94.5 % | 90-95% | 62% | yes |
![]() | 73% | 70 | 47-55% | less efficient |
![]() | 91.6 % | ? | 60 | ? |
![]() | 50.4 % | ? | ? | ? |
![]() | 96.4 % | 86.3% | 55.4 % | ? |
![]() | 81 % | ? | ? | ? |
![]() |
In the following table you can find some of the most practical data. Prices are actually dependent on agreement between nations and producers. For example the Pfizer BioNTech vaccine had substantial financial help from German and EU institutions, thus the price in EU is lower than in USA. Viceversa Moderna has a lower price in USA than in the EU
N. doses | Days Gap | Price per dose | EU approval | USA approval | Partners | Technique | ||
UK | ![]() ![]() | 2 | 85 | UK: 3$ US: 4$ EU: 2.15$ | Yes | ongoing | viral vector | |
DE USA | ![]() ![]() | 2 | 21 | EU: 14.70$ US: 19.50$ | Yes | Yes | Sanofi | mRNA |
USA | ![]() | 2 | 28 | EU: 18$ US: 15$ | Yes | Yes | mRNA | |
USA | ![]() | 1 | 8.50$ | Yes | Yes | viral vector | ||
RU | ![]() | 2 | 21-56 | 10 $ | ongoing | not applied | viral vector | |
ZH | ![]() | 2 | 21 | 60$ | not applied | not applied | viral vector | |
USA | ![]() | 2 | 21 | 16$ | ongoing | protein sub-units | ||
IN | ![]() | 2 | 28 | 2.90$ | not applied | not applied | viral vector | |
DE | ![]() | 2 | 28 | 12.25$ | ongoing | GSK, Bayer & Novartis | mRNA | |